Haemodialysis in haemophilia B: a case report. Challenges and strategies from a nephrology perspective.

J NephrolOct 30, 2026
Case ReportNephrologyHematology

Chiara Terzo, Rosario Maccarrone, Sandra La Rosa et al.

✦ AI-curated · Sources linked

Case in brief

A 68-year-old man with severe haemophilia B and kidney failure required kidney replacement therapy. He received prophylactic Idelvion® (albutrepenonacog alfa), then underwent arteriovenous fistula creation and started haemodialysis. No bleeding complications were reported. The report also reviews dialysis considerations in haemophilia B, including modality selection, vascular access, factor IX replacement and anticoagulation, and describes multidisciplinary planning to reduce bleeding risk.

What made this case unusual

The case demonstrates haemodialysis initiation, including arteriovenous fistula creation, in a patient with severe haemophilia B without reported bleeding complications under prophylactic factor IX replacement.

Diagnostic / clinical pearl

Severe haemophilia B does not necessarily preclude chronic haemodialysis; this case highlights the role of multidisciplinary planning, factor IX replacement and tailored anticoagulation to address bleeding risk.

Source

PubMed · PMID 42487221

Published in J Nephrol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchOncology (Medical)

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations.

This international consensus guideline addresses curative-intent management of de novo metastatic nasopharyngeal carcinoma, a population historically treated with palliative intent.

Lancet OncolOct 29, 2026Read summary
Clinical ResearchHematology

Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.

This open-label, multicentre, randomised phase 3 trial compared decitabine plus busulfan-cyclophosphamide (DAC-BuCy) with BuCy conditioning before allogeneic HSCT in 130 patients aged 14–65 years with KMT2A-rearranged…

Lancet HaematolOct 30, 2026Read summary
Clinical ResearchPediatrics

Prone positioning and high-frequency oscillatory ventilation in early paediatric acute respiratory distress syndrome (PROSpect): an international, two-by-two factorial, response-adaptive, phase 3, randomised controlled trial.

PROSpect was an international, two-by-two factorial, phase 3 randomised controlled trial comparing prone with supine positioning and high-frequency oscillatory ventilation (HFOV) with conventional mechanical ventilation…

LancetOct 30, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.